LLY

1,059.93

+1.47%↑

JNJ

205.53

+1.23%↑

ABBV

236.05

+2.86%↑

UNH

321.42

+2.57%↑

AZN

91.12

+2.47%↑

LLY

1,059.93

+1.47%↑

JNJ

205.53

+1.23%↑

ABBV

236.05

+2.86%↑

UNH

321.42

+2.57%↑

AZN

91.12

+2.47%↑

LLY

1,059.93

+1.47%↑

JNJ

205.53

+1.23%↑

ABBV

236.05

+2.86%↑

UNH

321.42

+2.57%↑

AZN

91.12

+2.47%↑

LLY

1,059.93

+1.47%↑

JNJ

205.53

+1.23%↑

ABBV

236.05

+2.86%↑

UNH

321.42

+2.57%↑

AZN

91.12

+2.47%↑

LLY

1,059.93

+1.47%↑

JNJ

205.53

+1.23%↑

ABBV

236.05

+2.86%↑

UNH

321.42

+2.57%↑

AZN

91.12

+2.47%↑

Search

Penumbra Inc

Atvērts

SektorsVeselības aprūpe

288.3 2.38

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

274.81

Max

288.81

Galvenie mērījumi

By Trading Economics

Ienākumi

581K

46M

Pārdošana

15M

355M

P/E

Sektora vidējais

66.629

106.172

Peļņas marža

12.927

Darbinieki

4,500

EBITDA

4M

55M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+8.36% upside

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

2.1B

11B

Iepriekšējā atvēršanas cena

285.92

Iepriekšējā slēgšanas cena

288.3

Ziņu noskaņojums

By Acuity

50%

50%

182 / 374 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Bearish Evidence

Penumbra Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 20. nov. 23:07 UTC

Tirgus saruna

Evidence Of Broad Australian Economic Upswing Mounts -- Market Talk

2025. g. 20. nov. 22:22 UTC

Tirgus saruna

Auckland Airport Has Edge Over Transurban In Infrastructure Stocks -- Market Talk

2025. g. 20. nov. 22:08 UTC

Tirgus saruna

Revenues of Texas Battery Projects Drop Sharply -- Market Talk

2025. g. 20. nov. 21:57 UTC

Peļņas

Walmart Reports Strong Sales Growth, Raises Outlook -- 5th Update

2025. g. 20. nov. 21:50 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Tech, Media & Telecom Roundup: Market Talk

2025. g. 20. nov. 21:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 20. nov. 21:50 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Health Care Roundup: Market Talk

2025. g. 20. nov. 21:50 UTC

Tirgus saruna
Peļņas

Financial Services Roundup: Market Talk

2025. g. 20. nov. 21:31 UTC

Peļņas

Nvidia's Strong Results Show AI Fears Are Premature -- Update

2025. g. 20. nov. 21:23 UTC

Peļņas
Iegādes, apvienošanās, pārņemšana

These Stocks Moved the Most Today: Nvidia, Exact Sciences, Walmart, AMD, Alphabet, Palo Alto Networks, and More -- Barrons.com

2025. g. 20. nov. 21:07 UTC

Peļņas

Intuit Earnings Beat Estimates as Company Leans Into AI Strategy -- Barrons.com

2025. g. 20. nov. 21:06 UTC

Peļņas

Webull 3Q Rev $156.9M >BULL

2025. g. 20. nov. 21:06 UTC

Peļņas

Webull 3Q EPS 7c >BULL

2025. g. 20. nov. 21:05 UTC

Peļņas

Intuit 1Q Sales Jump, CFO Cites AI Demand From Mid-Sized Businesses -- Interview

2025. g. 20. nov. 21:04 UTC

Peļņas

Mid-Sized Businesses Want to Automate Tasks With AI, Intuit CFO Says >INTU

2025. g. 20. nov. 21:04 UTC

Peļņas

Intuit's AI Offerings Attracted More Mid-Sized Businesses in 1Q, CFO Says >INTU

2025. g. 20. nov. 21:04 UTC

Peļņas

Intuit Earnings Beat Estimates as Company Leans Into AI Strategy -- Barrons.com

2025. g. 20. nov. 21:00 UTC

Peļņas

Intuit Sees 2Q Rev $4.52B-$4.55B >INTU

2025. g. 20. nov. 21:00 UTC

Peļņas

Intuit Sees FY26 GAAP Operating Income $5.78B to $5.86B

2025. g. 20. nov. 21:00 UTC

Peļņas

Intuit Sees 2Q Adj EPS $3.63-Adj EPS $3.68 >INTU

2025. g. 20. nov. 21:00 UTC

Peļņas

Intuit Expects FY26 Global Business Solutions Rev Growth of 15.5% to 16.5%, Excluding Mailchimp

2025. g. 20. nov. 21:00 UTC

Peļņas

Intuit Expects FY26 Consumer Rev Growth of 8% to 9%

2025. g. 20. nov. 21:00 UTC

Peļņas

Intuit Expects FY26 Global Business Solutions Rev Growth of 14% to 15%

2025. g. 20. nov. 21:00 UTC

Peļņas

Intuit Backs FY26 Rev $21B-$21.19B >INTU

2025. g. 20. nov. 21:00 UTC

Peļņas

Intuit Backs FY26 Adj EPS $22.98-Adj EPS $23.18 >INTU

2025. g. 20. nov. 21:00 UTC

Peļņas

Intuit 1Q Consumer Rev $894M

2025. g. 20. nov. 21:00 UTC

Peļņas

Intuit Sees 2Q EPS $1.76-EPS $1.81 >INTU

2025. g. 20. nov. 21:00 UTC

Peļņas

Intuit Backs FY26 Guidance

2025. g. 20. nov. 21:00 UTC

Peļņas

Intuit Backs FY26 EPS $15.49-EPS $15.69 >INTU

2025. g. 20. nov. 21:00 UTC

Peļņas

Intuit 1Q Global Business Solutions Rev $3B

Salīdzinājums

Cenas izmaiņa

Penumbra Inc Prognoze

Cenas mērķis

By TipRanks

8.36% augšup

Prognoze 12 mēnešiem

Vidējais 306.82 USD  8.36%

Augstākais 355 USD

Zemākais 266 USD

Pamatojoties uz 13 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Penumbra Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

13 ratings

10

Pirkt

3

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

288.28 / 292.9394Atbalsts un pretestība

Īstermiņā

Bearish Evidence

Vidējā termiņā

Bullish Evidence

Ilgtermiņā

Weak Bullish Evidence

Noskaņojums

By Acuity

182 / 374 Rangs Veselības aprūpe

Ziņu noskaņojums

Neutral

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Penumbra Inc

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX Select, BENCHMARK, BMX96, BMX81, DDC, SENDit, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization Device, aspiration tubing, and aspiration pump under the Penumbra RED, JET, ACE, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as Penumbra SMART COIL, a detachable coil to treat patients with a wide range of neurovascular lesions; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers an immersive 3D computer-based technology platform under the real immersive system brand; and neurosurgical tools, such as Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.
help-icon Live chat